“联通世界的‘中国之桥’”

Core Insights - The China International Import Expo (CIIE) serves as a valuable platform for cross-industry and cross-border dialogue, providing significant opportunities for global companies to deepen cooperation in the Chinese market [2] - AstraZeneca has consistently participated in the CIIE, showcasing over 40 innovative drugs introduced to the Chinese market over the past 30 years, including two globally innovative cancer drugs at this year's expo [2] - AstraZeneca has signed 14 licensing agreements with Chinese innovative pharmaceutical companies in 2023, aiming to promote local research achievements internationally [2] Company Developments - China is AstraZeneca's second-largest market globally, and the company has been increasing its investment in local research, production, and supply chain systems [3] - AstraZeneca has announced expansions of its production bases in Wuxi, Taizhou, and Qingdao over the past three expos, with a new strategic research center in Beijing launched on October 25, 2023, as part of a $2.5 billion investment plan [3] - The new research center features advanced AI and data science capabilities to accelerate the transition of early drug research results to clinical development [3] Industry Context - The Chinese government is committed to expanding openness and attracting foreign investment, which enhances global companies' confidence in China's economic development [3] - AstraZeneca aims to contribute to the "Healthy China 2030" initiative and promote high-quality development through continued investment and collaboration with local partners [3]